ONC212, also known as ONC-212, is a small molecule anti-cancer drug that is currently in preclinical trials. It has shown promise in treating various types of cancer, including solid tumors and hematological malignancies.
Chemical Name
The chemical name of ONC212 is (S)-2-(1-butyl-4-chloro-1H-imidazol-5-yl)-N-(quinolin-6-yl)propanamide.
Molecular Formula
The molecular formula of ONC212 is C21H22ClN3O1.
Formula Weight
The formula weight of ONC212 is 369.87 g/mol.
CAS No.
The CAS number for ONC212 is 1807861-48-8.
Top Ten Keywords and Synonyms from Google
Health Benefits of ONC212
ONC212 is still undergoing preclinical trials, but it has shown promise in treating various types of cancer. In preclinical studies, ONC212 has been shown to induce apoptosis, or programmed cell death, in cancer cells while leaving healthy cells unharmed. This makes it an attractive option for cancer treatment because it may result in fewer side effects than traditional chemotherapy.
Potential Effects
ONC212 has several potential effects, including:
Product Mechanism
ONC212 works by activating the TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) pathway, leading to apoptosis in cancer cells. The TRAIL pathway is a natural mechanism used by the immune system to eliminate damaged or abnormal cells. ONC212 enhances this process by binding to a protein called TRAIL receptor DR5, which activates the apoptotic pathway.
Safety
ONC212 is still undergoing preclinical trials, and its safety profile is not fully understood. However, early studies suggest that it may have fewer side effects than traditional chemotherapy because it specifically targets cancer cells while leaving healthy cells unharmed. Further research is needed to determine the long-term safety of ONC212.
Side Effects
ONC212 may cause side effects, including:
Dosing Information
The dosing of ONC212 varies depending on the individual's condition and response to treatment. It is usually administered orally, and the recommended dose ranges from 25-200 mg per day. The dose may be adjusted based on the individual's body weight and overall health.
Conclusion
ONC212 is a novel anti-cancer drug that shows promising results in preclinical trials. It works by activating the TRAIL pathway, leading to apoptosis in cancer cells. ONC212 may have fewer side effects than traditional chemotherapy because it specifically targets cancer cells while leaving healthy cells unharmed. While still undergoing preclinical trials, ONC212 offers hope for individuals with various types of cancer. If you are experiencing symptoms of cancer or other health conditions, it is important to seek medical attention and follow the guidance of healthcare professionals
